BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Native Antigen Company Ltd: Toxins & Toxoids of Clostridium Difficile Ribotypes 027 and 078


4/5/2013 10:29:51 AM

April 2013. The Native Antigen Company (NAC); http://thenativeantigencompany.com announces the release of highly purified toxins and toxoids of Clostridium difficile ribotypes 027 and 078 for use in research, vaccine development and by IVD manufacturers.

Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in economically developed countries. CDI is primarily linked with hospital admission and prior antimicrobial treatment. Although significant advances have been made to reduce incidence, a number of hypervirulent and highly transmissible strains have recently emerged. Resultant healthcare challenges are compounded as widespread use of antibiotics encourages both the emergence of resistant strains and reoccurrence of infection, especially in the elderly.

The availability of these cost effective, high performance toxins and toxoids is timely and supports the increasing healthcare focus on combating these hypervirulent strains.

To satisfy a broad range of applications, the products are offered as separate preparations in a variety of vial sizes and are suitable for long term storage,

For more information please contact Andrew Maxwell, CEO Native Antigen Company +44 (0) 1869 238067, amaxwell@thenativeantigencompany.com

or visit www.thenativeantigencompany.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES